Regen Biopharma (RGBP) Ratios
Regen Biopharma Ratios
RGBP's free cash flow for Q3 2026 was $-24.07K. For the 2026 fiscal year, RGBP's free cash flow was decreased by $-5.00 and operating cash flow was $-24.07K. See a summary of the company’s cash flow.
| Ratios | Sep 25 | Sep 24 | Sep 23 | Sep 22 | Sep 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.04 | 0.03 | 0.02 | 0.04 | 0.07 |
| Quick Ratio | 0.04 | 0.03 | 0.02 | 0.04 | 0.07 |
| Cash Ratio | 0.00 | 0.00 | 0.02 | 0.01 | 0.05 |
| Solvency Ratio | -0.19 | -0.03 | 0.54 | 0.30 | -0.45 |
| Operating Cash Flow Ratio | -0.06 | -0.13 | -0.03 | -0.07 | -0.08 |
| Short-Term Operating Cash Flow Coverage | -0.48 | -0.85 | -0.29 | -0.48 | -0.32 |
| Net Current Asset Value | $ -6.28M | $ -5.21M | $ -5.33M | $ -8.26M | $ -13.70M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 2.89 | 4.59 | 2.14 | 2.28 | 2.96 |
| Debt-to-Equity Ratio | -0.13 | -0.16 | -0.15 | -0.16 | -0.27 |
| Debt-to-Capital Ratio | -0.14 | -0.19 | -0.17 | -0.19 | -0.36 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | -0.03 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.04 | -0.03 | -0.07 | -0.07 | -0.09 |
| Debt Service Coverage Ratio | -1.01 | -0.39 | 3.40 | 1.96 | -1.57 |
| Interest Coverage Ratio | -1.61 | -1.69 | -2.22 | -1.33 | -0.55 |
| Debt to Market Cap | 2.50 | 1.93 | 0.12 | 0.08 | 0.08 |
| Interest Debt Per Share | 0.04 | 0.26 | 0.15 | 0.49 | 1.97 |
| Net Debt to EBITDA | -0.78 | -1.95 | 0.20 | 0.41 | -0.46 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 100.00% | 100.00% | 78.77% | 85.40% |
| EBIT Margin | -449.81% | -397.36% | 514.03% | 1145.99% | -3737.28% |
| EBITDA Margin | -427.76% | -176.70% | 1318.48% | 1270.82% | -3620.00% |
| Operating Profit Margin | -143.11% | -176.28% | -290.41% | -144.36% | -117.41% |
| Pretax Profit Margin | -538.76% | -282.38% | 489.09% | 1037.72% | -3951.66% |
| Net Profit Margin | -538.76% | -282.38% | 432.87% | 945.58% | -3951.66% |
| Continuous Operations Profit Margin | -538.76% | -282.38% | 489.09% | 1037.72% | -3951.66% |
| Net Income Per EBT | 100.00% | 100.00% | 88.50% | 91.12% | 100.00% |
| EBT Per EBIT | 376.47% | 160.19% | -168.41% | -718.82% | 3365.67% |
| Return on Assets (ROA) | -464.08% | -376.10% | 289.58% | 398.39% | -558.12% |
| Return on Equity (ROE) | 20.29% | 12.86% | -20.06% | -27.71% | 50.16% |
| Return on Capital Employed (ROCE) | 5.39% | 8.03% | 13.87% | 4.23% | 1.49% |
| Return on Invested Capital (ROIC) | 6.19% | 9.52% | 15.80% | 5.03% | 2.03% |
| Return on Tangible Assets | -464.08% | -376.10% | 289.58% | 398.39% | -558.12% |
| Earnings Yield | -401.36% | -158.24% | 16.04% | 14.55% | -14.74% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.15 | 2.49 | 0.00 | 0.93 | 0.78 |
| Payables Turnover | 0.00 | 2.60 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.86 | 1.33 | 0.67 | 0.42 | 0.14 |
| Working Capital Turnover Ratio | -0.04 | -0.05 | -0.04 | -0.02 | -0.02 |
| Cash Conversion Cycle | 316.11 | 6.14 | 0.00 | 394.07 | 466.54 |
| Days of Sales Outstanding | 316.11 | 146.38 | 0.00 | 394.07 | 466.54 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 140.25 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 316.11 | 146.38 | 0.00 | 394.07 | 466.54 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.02 | -0.17 | -0.02 | -0.19 | -0.56 |
| Free Cash Flow Per Share | -0.02 | -0.17 | -0.02 | -0.19 | -0.56 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -57972.33 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -57972.33 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -0.48 | -0.85 | -0.23 | -0.48 | -0.32 |
| Operating Cash Flow to Sales Ratio | -1.62 | -2.93 | -0.74 | -2.58 | -6.61 |
| Free Cash Flow Yield | -120.80% | -164.20% | -2.72% | -3.97% | -2.46% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.25 | -0.63 | 6.23 | 6.87 | -6.79 |
| Price-to-Sales (P/S) Ratio | 1.34 | 1.78 | 26.99 | 64.98 | 268.13 |
| Price-to-Book (P/B) Ratio | -0.05 | -0.08 | -1.25 | -1.90 | -3.40 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.83 | -0.61 | -36.71 | -25.22 | -40.59 |
| Price-to-Operating Cash Flow Ratio | -0.83 | -0.61 | -36.71 | -25.22 | -40.59 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.00 | -0.10 | -0.06 | 0.04 |
| Enterprise Value Multiple | -1.10 | -2.96 | 2.25 | 5.52 | -7.87 |
| Enterprise Value | 1.11M | 1.24M | 7.02M | 16.53M | 48.76M |
| EV to EBITDA | -1.10 | -2.96 | 2.25 | 5.52 | -7.87 |
| EV to Sales | 4.69 | 5.23 | 29.67 | 70.17 | 284.82 |
| EV to Free Cash Flow | -2.90 | -1.78 | -40.36 | -27.23 | -43.11 |
| EV to Operating Cash Flow | -2.90 | -1.78 | -40.36 | -27.23 | -43.11 |
| Tangible Book Value Per Share | -0.27 | -1.26 | -0.72 | -2.56 | -6.72 |
| Shareholders’ Equity Per Share | -0.27 | -1.26 | -0.72 | -2.56 | -6.72 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.01 | 0.06 | 0.03 | 0.08 | 0.09 |
| Net Income Per Share | -0.05 | -0.16 | 0.14 | 0.71 | -3.37 |
| Tax Burden | 1.00 | 1.00 | 0.89 | 0.91 | 1.00 |
| Interest Burden | 1.20 | 0.71 | 0.95 | 0.91 | 1.06 |
| Research & Development to Revenue | 0.05 | 0.65 | 0.90 | 1.17 | 0.21 |
| SG&A to Revenue | 2.00 | 2.11 | 2.75 | 1.27 | 1.96 |
| Stock-Based Compensation to Revenue | 0.00 | 0.02 | 1.47 | 0.19 | 0.00 |
| Income Quality | 0.30 | 0.80 | -0.15 | -0.25 | 0.17 |
Currency in USD
